



28/05/2025

To

The Listing Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai 400 001.

Dear Sir/Madam,

Subject: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR) - Outcome of Board Meeting held on Wednesday, May 28th 2025.

REF: Scrip Code – 544365

Further to our intimation dated 21st May 2025, we wish to inform you that the Board of Directors of the Company, at its meeting held today, i.e., 28th May 2025, inter alia, considered and approved the following:

1. Approval of Financial Results:

Audited Financial Results of the Company for the half year and year ended 31st March 2025.

2. Re-appointment of Internal Auditors:

Re-appointment of M/s J V & Co, Chartered Accountants, Salem, as the Internal Auditors of the company for the financial year 2025 – 26.

3. Re-appointment of Secretarial Auditors:

Re-appointment of M/s. Suryah & Dinesh Associates LLP, Practicing Company Secretaries, Salem, as the Secretarial Auditors of the company for the financial year 2025 – 26.

4. Statement of Deviation or Variation:

Statement of Deviation or Variation in the utilization of proceeds from the Initial Public Offer (IPO) for the half year ended 31st March, 2025, with *Nil* deviation, pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

 Reg. Off : 51/24, Shanmuga Hospital Building, Saradha College Road, Salem - 636 007.

 0427-2706666 / 87540 33833

 info@shanmugahospital.com | www.shanmugahospital.com





5. Opening of New Nephro Care Unit:

In-principle approval for the opening of a *Nephro Care Unit* in the near future. The final venue, operational details, and launch timeline will be announced in due course.

6. Closure of Business Unit:

Closure of Shanmuga Pharmacy & Diagnostics, located at 608, Bazar Street, Salem 636001, with effect from 31st May, 2025.

The requisite details as per the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Schedule III and SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is enclosed

The meeting commenced at 04.00 P.M. and concluded at 06:10 P.M.

Thanking you,

Yours Sincerely,

FOR SHANMUGA HOSPITAL LIMITED

KANNAN ANJANA MARAGATHAM
COMPANY SECRETARY & COMPLIANCE OFFICER
M.NO:A70080

SHANMUGA HOSPITAL LIMITED
(formerly known as Shanmuga Hospital Private Limited)
CIN: L85110TZ2020PLC033974
51/24, Saradha College Road, Salem, Tamil Nadu, India-636007

Rs. in Lakhs

STATEMENT OF ASSETS AND LIABILITIES AS AT 31ST MARCH, 2025

Particulars	As at March 31, 2025	As at March 31, 2024
	Audited	Audited
I. EQUITY AND LIABILITIES		
1 SHAREHOLDERS' FUNDS		
(a) Share Capital	1,361.30	979.50
(b) Reserves and Surplus	2,608.51	733.85
2 NON-CURRENT LIABILITIES		
(a) Long-Term Borrowings	359.35	359.35
(b) Deferred Tax Liabilities (Net)	41.35	27.58
(c) Long-Term Provisions	11.04	4.62
3 CURRENT LIABILITIES		
(a) Short-Term Borrowings	402.10	542.53
(b) Trade Payables		
(i) Total outstanding dues of Micro Enterprises and Small Enterprises and	12.11	11.98
(ii) Total outstanding dues of creditors other than Micro Enterprises and Small Enterprises	366.04	492.65
(c) Other Current Liabilities	115.59	77.68
(d) Short-Term Provisions	0.72	161.77
TOTAL	5,278.10	3,391.52
II. ASSETS		
1 NON-CURRENT ASSETS		
(a) Property, Plant & Equipment and Intangible Assets		
(i) Property, Plant & Equipment	2,242.71	1,584.62
(ii) Capital Work-in-Progress	-	433.68
(b) Non-Current Investments	2.74	2.48
(c) Other Non-Current Assets	31.64	16.85
2 CURRENT ASSETS		
(a) Inventories	288.97	195.16
(b) Trade Receivables	796.05	696.15
(c) Cash & Bank Balances	1,258.93	209.92
(d) Short-Term Loans and Advances	578.55	33.57
(e) Other Current Assets	78.51	219.10
TOTAL	5,278.10	3,391.52

Figures of the previous period / year have been rearranged / reclassified wherever necessary, to correspond with Current Period / year presentation

For and on behalf of the Board of Directors of
SHANMUGA HOSPITAL LIMITED
(formerly known as Shanmuga Hospital Private Limited)

Place: Salem
Date: 28/05/2025

P. PRABU SANKAR
Director cum CEO
DIN: 08772888

<p style="text-align: center;">SHANMUGA HOSPITAL LIMITED (formerly known as Shanmuga Hospital Private Limited) CIN: L85110TZ2020PLC033974 51/24, Saradha College Road, Salem, Tamil Nadu, India-636007</p>					
Rs. in Lakhs					
FINANCIAL RESULTS FOR THE HALF YEAR ENDED AND FINANCIAL YEAR ENDED ON 31ST MARCH 2025					
Particulars	For the Half year ended 31st March, 2025	For the Half year ended 30th September, 2024	For the Half year ended 31st March, 2024	Year ended 31st March, 2025	Year ended 31st March, 2024
	Audited	Audited	Audited	Audited	Audited
I Revenue From Operations	2,323.15	2,462.18	2,188.88	4,785.33	4,303.74
II Other Income	2.72	20.63	14.09	23.35	35.04
III Total Income (I+II)	2,325.87	2,482.81	2,202.97	4,808.67	4,338.78
IV Expenses					
Cost of Consumption	806.89	965.85	906.16	1,772.74	1,696.38
Employee Benefits Expenses	254.71	304.54	166.17	559.25	323.64
Finance Costs	28.70	33.96	28.82	62.67	60.81
Depreciation & Amortisation Expenses	110.06	105.74	83.82	215.80	130.39
Other Expenses	880.37	749.10	684.88	1,629.47	1,424.06
Total Expenses (IV)	2,080.73	2,159.20	1,869.85	4,239.93	3,635.29
V Profit Before Exceptional and Extraordinary Items and Tax (III-IV)	245.14	323.60	333.12	568.74	703.49
VI Exceptional Items	-	-	-	-	-
VII Profit before extraordinary items and tax (V-VI)	245.14	323.60	333.12	568.74	703.49
VIII Extraordinary items					
Prior Period Item	-	-	1.30	-	1.30
IX Profit before tax (VII-VIII)	245.14	323.60	331.82	568.74	702.19
X Tax Expense:					
(1) Current Tax	53.45	80.39	99.38	133.84	165.31
(2) Deferred Tax	9.85	3.92	(15.35)	13.77	12.04
(3) Tax Adjustment of Earlier Years	0.46			0.46	-
XI Profit (Loss) for the period from continuing operations (IX-X)	181.38	239.29	247.79	420.67	524.85
XII Profit/(Loss) For The Period (XI)	181.38	239.29	247.79	420.67	524.85
XIII Earnings per equity share: (In Rs.)					
(1) Basic	1.64	2.44	2.53	4.03	5.36
(2) Diluted	1.64	2.44	2.53	4.03	5.36
Notes on Standalone Financial Results:					
<p>The above results which are published in accordance with Regulations 33 of SEBI (Listing Obligation & Disclosure Requirements), 2015 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on May 28, 2025. The Financial results have been prepared in accordance with the Accounting Standards ("AS") as prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of Companies (Account) Rules 2014 by the Ministry of Corporate Affairs and amendments thereof.</p> <p>As per Ministry of Corporate Affairs Notification dated February 16, 2015, Companies whose securities are listed on SME Exchange as referred to in Chapter XB of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009 are exempted from the compulsory requirement of adoption of Ind AS.</p> <p>The Company has issued 38,18,000 Equity share of Rs.10/- each at a premium of Rs.44/- each by way of Initial Public Offer ("IPO") and got listed on SME Platform of BSE Limited on 21st February, 2025. Accordingly these audited Financial result for the year ended March 31, 2025 are drawn in accordance with the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.</p>					
Rs. in Lakhs					
S.No	Objective of the Issue	Amount Alloted for the object	Amount Utilised till March 31, 2025	Amount Unutilised till March 31, 2025	Remarks
1	Issue Related Expenses	225.94	225.94	-	NA
2	General Corporate Purposes	383.28	383.28	-	NA
3	Capex purposes	1,452.50	337.00	1,115.50	The unutilized amount is in the form of Fixed Deposits for future utilization. The Unutilised portion is proposed to be utilised within the month of May 2025
<p>The figures for the corresponding previous period have been regrouped / reclassified wherever necessary</p> <p>The balance appearing under the Trade Payables Loans and Advances, Other Current Liabilities are subjected to confirmation and reconciliation and consequent adjustments, if any, will be accounted for in the year of confirmation and / or reconciliation.</p> <p>As the Company collectively operates only in one business segment, hence it is reporting its results in single segment. Therefore, Segment disclosure is not applicable.</p> <p>There were no Exceptional and Extra- Ordinary items for the reporting period</p>					
<p style="text-align: right;">For and on behalf of the Board of Directors of SHANMUGA HOSPITAL LIMITED (formerly known as Shanmuga Hospital Private Limited)</p>					
<p style="text-align: right;">P. PRABU SANKAR Director cum CEO DIN:8772888</p>					
<p>Place: Salem Date: 28-05-2025</p>					

SHANMUGA HOSPITAL LIMITED
(formerly known as Shanmuga Hospital Private Limited)
CIN: L85110TZ2020PLC033974
51/24, Saradha College Road, Salem, Tamil Nadu, India-636007

Rs. in Lakhs

CASH FLOW STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2025

Particulars	As at March 31, 2025	As at March 31, 2024
	Audited	Audited
A CASH FLOWS FROM OPERATING ACTIVITIES		
Net Profit Before Tax	568.74	703.49
Adjustments for:		
Depreciation	215.80	130.39
Provision for Gratuity	7.13	1.51
Interest Expenses	55.90	52.03
Dividend income	(0.06)	-
Interest Income	(6.90)	(2.04)
Operating Profit before working capital changes:	840.60	885.39
Adjustments for changes in working capital:		
(Increase)/Decrease in Inventories	(93.80)	(37.44)
(Increase)/Decrease in Trade Receivables	(99.90)	(110.21)
(Increase)/Decrease in Short term Loans & Advances (including other bank balances)	(1,666.56)	(5.07)
(Increase)/Decrease in Other Current assets	140.58	(14.47)
Increase/(Decrease) in Trade payables	(126.48)	355.81
Increase/(Decrease) in Other Current Liabilities	37.90	39.29
Cash generated from operations	(967.65)	1,113.30
Less: Income Taxes Paid	(296.06)	(155.39)
NET CASH FROM OPERATING ACTIVITIES (A)	(1,263.71)	957.91
B CASH FLOWS FROM INVESTING ACTIVITIES		
Interest Received	6.90	2.04
Dividend income	0.06	-
Purchase of Property, Plant and Equipment	(440.22)	(1,151.30)
(Increase)/Decrease in Non-Current Investments	(0.26)	(0.49)
(Increase)/Decrease in Other Non Current Assets	(14.79)	(9.57)
NET CASH USED IN INVESTING ACTIVITIES (B)	(448.30)	(1,159.31)
C CASH FLOWS FROM FINANCING ACTIVITIES		
Interest paid	(55.90)	(52.03)
Increase/(Decrease) in Long Term Borrowings	-	(42.56)
Increase/(Decrease) in Short Term Borrowings	(140.43)	179.45
Proceeds from issue of equity shares less issue costs	1,835.78	5.00
NET CASH USED IN FINANCING ACTIVITIES (C)	1,639.45	89.85
D NET INCREASE IN CASH AND CASH EQUIVALENT (A+B+C)	(72.55)	(111.55)
Opening Cash and Cash Equivalents	209.92	321.47
CLOSING CASH AND CASH EQUIVALENT	137.36	209.92

Particulars	As at March 31, 2025	As at March 31, 2024
	Audited	Audited
Notes to Cash & Bank Balances:		
Cash & Bank balances comprise of		
Cash in Hand	39.02	38.17
Balance with Banks in Current Account	98.34	171.75
Subtotal (a)	137.36	209.92
Balance with Banks in Deposit Account (having maturity less than 12 months)	1,121.58	-
Subtotal (b)	1,121.58	-
TOTAL (a) + (b)	1,258.93	209.92

Notes*

- (i) The Cash flow statement is prepared as per AS 3 "Cash flow statement" where balance with banks in Deposit Account not treated as part of Cash and cash equivalent.
(ii) Figures in brackets are outflows / deductions.
(iii) The above Cash Flow Statement is prepared under the Indirect Method as set out in the Accounting Standards (AS-3)- Statement of Cash Flows.

For and on behalf of the Board of Directors of
SHANMUGA HOSPITAL LIMITED
(formerly known as Shanmuga Hospital Private Limited)

Place: Salem
Date: 28/05/2025

P. PRABU SANKAR
Director cum CEO
DIN: 08772888



PPN AND COMPANY

CHARTERED ACCOUNTANTS

No.2, IV Cross Street, Sterling Road, Nungambakkam, Chennai - 600 034.
(Near to Loyola College) Ph: 044-2828 0033, Cell: 98844 48912.
E-mail: info@ppnaco.com | Web: www.ppnaco.com | www.ppnaco.co.in

Independent Auditor's Report for the Half Year ended and Year ended 31-03-2025

(Audit of Standalone Financial Results of the Group Pursuant to Regulation 33 of the SEBI
(Listing Obligation and Disclosure Requirements), Regulation, 2015, as amended)

To

The Board of Directors,
SHANMUGA HOSPITAL LIMITED,

Report on the Audit of the Standalone Financial Results

Opinion:

We have audited the standalone financial results of "Shanmuga Hospital Limited" (herein after referred to as the "Company"), for the year ended 31st March, 2025 ("the Statement"), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015 ('the Regulation') as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial results;

- give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2025, and profit for the year ended on that date; and
- is presented in accordance with the requirements of Regulation 33 of the Listing Regulations



Basis for Opinion:

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under these standards are elaborated upon in the Auditor's Responsibilities for the Audit of the Financial Results segment of our report. Our independence from the Company is in full compliance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and its associated Regulations. Furthermore, we have conscientiously met all other ethical obligations in alignment with these regulations and the Code of Ethics. We maintain confidence that the audit evidence gathered is both sufficient and appropriate to provide a basis for audit opinion.

Responsibilities of Management for the Standalone Financial Results:

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial results that give true and fair view of the financial position, financial information of the company in accordance with the accounting principles generally accepted in India, including the measurement principles laid down in the Accounting Standard – 25, specified under section 133 of the Act, along with the relevant rule issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgements and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.



In preparing the financial results, the management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial results:

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of the audit and in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also have:

- Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.



- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management and the Board of Directors.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease or to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Financial Results of the entities within the group to express an opinion on the Financial results.
Materiality is the magnitude of misstatements in the Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Standalone Financial Results may be influenced.

We consider quantitative materiality and qualitative factors in -

- Planning the scope of our audit work and in evaluating the results of our work; and
- to evaluate the effect of any identified misstatements in the Standalone Financial Results

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters:

The Standalone Annual Financial Results dealt with by this report have been prepared for the express purpose of filing with Stock Exchanges. These results are based on and should be read with the audited Standalone Financial results of the Company for the year ended 31st March 2025 on which we issued an unmodified audit opinion.

The Statement includes the results for the half year ended 31st March 2025, being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the first half of the year of the current financial year which were subject to limited review by us. Our report on the Statement is not modified in respect of this matter.

DATE: 28/05/2025

PLACE: Salem

For P P N AND COMPANY
Chartered Accountants
Firm Reg No:013623S



R. Rajaram
Partner

M.No:238452

UDIN No: 25238452BMHSUB9357



28/05/2025

To

The Listing Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai 400 001.

Dear Sir/Madam,

SUB: Declaration for audit reports with unmodified opinion Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and amended Regulations, 2016:

We hereby declare that M/s PPN AND COMPANY, Chartered Accountants, the Statutory Auditors of the Company have given the audit report with unmodified opinion on the audited financial results of the Company for the year ended on 31-03-2025.

Thanking you,

Yours Sincerely,

FOR SHANMUGA HOSPITAL LIMITED

KARTHICK
CHIEF FINANCIAL OFFICER



Shanmuga Hospital Ltd.,

A Legacy of caring

(Formally Known as Shanmuga Hospital Private Limited)

CIN : L85110TZ2020PLC033974

ANNEXURE:

Sl.NO	Particulars	Details
1.	Name of the Auditor	M/s J.V.Co , Chartered Accountants FRN: 006382S
2.	Reason for change viz. appointment, resignation, removal, death or otherwise	Re-appointment as Internal Auditor of the Company.
3.	Date of appointment & term of appointment	May 28, 2025 For the Financial Year 2025- 26
4.	Brief Profile (in case of appointment)	J.V. & Co. is a partnership firm of Chartered Accountants based in Salem, with a branch in Tirupur, and has over thirty years of professional experience. The firm specializes in various areas including valuations, internal audits, statutory audits, tax audits, transfer pricing audits, payroll audits, stock audits, and more. J.V. & Co. is also empaneled with the Comptroller and Auditor General (CAG) of India, New Delhi, for conducting audits of government and public sector undertakings.
5.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

 Reg. Off : 51/24, Shanmuga Hospital Building, Saradha College Road, Salem - 636 007.

 0427-2706666 / 87540 33833

 info@shanmugahospital.com | www.shanmugahospital.com





Shanmuga Hospital Ltd.,

A Legacy of caring

(Formally Known as Shanmuga Hospital Private Limited)

CIN : L85110TZ2020PLC033974

ANNEXURE:

Sl.NO	Particulars	Details
1.	Name of the Auditor	M/s Suryah and Dinesh Associates LLP
2.	Reason for change viz. appointment, resignation, removal, death or otherwise	Re-appointment as Secretarial Auditor of the Company.
3.	Date of appointment & term of appointment	May 28, 2025 For the Financial year 2025-26.
4.	Brief Profile (in case of appointment)	A firm of Company Secretaries with offices in Salem and Chennai, having peer-reviewed status and over three years of professional practice. Specialized in providing services in Company Law, SEBI Regulations, FEMA Compliance, Intellectual Property Rights, Corporate Governance, Legal Due Diligence, Startup Advisory, and Representation before NCLT and Regulatory Bodies. The firm is led by experienced professionals with a strong background in corporate legal matters, policy advisory, and secretarial services for both listed and unlisted companies across India.
5.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

 Reg. Off : 51/24, Shanmuga Hospital Building, Saradha College Road, Salem - 636 007.

 0427-2706666 / 87540 33833

 info@shanmugahospital.com | www.shanmugahospital.com





Shanmuga Hospital Ltd.,

A Legacy of caring

(Formerly Known as Shanmuga Hospital Private Limited)

CIN : L85110TZ2020PLC033974

28/05/2025

To

The Listing Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai 400 001.

Dear Sir/Madam,

SUB: Submission of details of Outstanding Qualified Borrowings and Incremental Qualified Borrowings for the financial year 2024 - 25.

REF: SEBI Circular No. SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated 19th October 2023.

This has reference to the above subject.

S.No	Particulars	Amount (Rs. In Crores)
1	Outstanding Qualified Borrowings at the start of the financial year.	359.35
2	Outstanding Qualified Borrowings at the end of the financial year	359.35
3	Highest credit rating of the company relating to the unsupported bank borrowings or plain vanilla bonds, which have no structuring/support-built in.	NIL
4	Incremental borrowing done during the year.	NIL
5	Borrowings by way of issuance of debt securities during the year	NIL

Thanking you,

Yours Sincerely,

FOR SHANMUGA HOSPITAL LIMITED

KARTHICK
CHIEF FINANCIAL OFFICER

 Reg. Off : 51/24, Shanmuga Hospital Building, Saradha College Road, Salem - 636 007.

 0427-2706666 / 87540 33833

 info@shanmugahospital.com | www.shanmugahospital.com





Shanmuga Hospital Ltd.,

A Legacy of caring

(Formally Known as Shanmuga Hospital Private Limited)

CIN : L85110TZ2020PLC033974

28/05/2025

To

The Listing Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai 400 001.

Dear Sir/Madam,

Subject: Statement on Deviation or Variation of funds under Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations)

Ref: Scrip Code – 544365

Pursuant to Regulation 32 of the SEBI Listing Regulations and SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019 and SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023, please note that there are no deviation(s) or variation(s) in respect of the utilization of the proceeds of the Initial Public Offer (“IPO”) of the Company during the half year ended 31st March 2025. A statement in this regard is enclosed as Annexure - A.

The aforesaid statement has been reviewed by the Audit Committee and taken on record by the Board at their respective meetings held on 28th May 2025.

Kindly take the same on record.

Thanking you,

Yours Sincerely,

FOR SHANMUGA HOSPITAL LIMITED

PANNEERSELVAM PRABU SANKAR
EXECUTIVE DIRECTOR & CEO
DIN:08772888

 Reg. Off : 51/24, Shanmuga Hospital Building, Saradha College Road, Salem - 636 007.

 0427-2706666 / 87540 33833

 info@shanmugahospital.com | www.shanmugahospital.com





Shanmuga Hospital Ltd.,

A Legacy of caring

(Formally Known as Shanmuga Hospital Private Limited)

CIN : L85110TZ2020PLC033974

STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE.

<u>Statement on deviation / variation in utilization of funds raised</u>	
Name of listed entity	Shanmuga Hospital Limited
Mode of Fund Raising	Public Issue
Date of Raising Funds	18-02-2025(Date of Allotment)
Amount Raised (Rs. In Lakhs)	2061.72
Report filed for Half Year ended	31.03.2025
Monitoring Agency	Not Applicable
Monitoring Agency Name, if applicable	Not Applicable
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable
If Yes, Date of shareholder Approval	Not Applicable
Explanation for the Deviation / Variation	Not Applicable
Comments of the Audit Committee after review	Nil
Comments of the auditors, if any	Nil

Objects for which funds have been raised and where there has been a deviation, in the following table:

(Rs. In lakhs)

Sr. No.	Object as disclosed in the Offer Document	Amount disclosed in the Offer Document (Rs. In Lakhs)	Actual Utilised Amount (Rs. In Lakhs)	Unutilised Amount (Rs. In Lakhs)	Deviation/ Variation, if any	Remarks
1	Capital Expenditure	1,452.50	337.00	1115.50	NA	The unutilized amount is in the form of Fixed Deposits for future utilisation. The Unutilised portion is proposed to be utilised within the month of May 2025.
2	Issue related expenses	225.94	225.94	0.00	NA	Nil
3	General Corporate Purposes	383.28	383.28	0.00	NA	Nil
	Total	2061.72	946.22	1115.50	NA	NA

FOR SHANMUGA HOSPITAL LIMITED

PANNEERSELVAM PRABU SANKAR

EXECUTIVE DIRECTOR & CEO

DIN:08772888

Reg. Off : 51/24, Shanmuga Hospital Building, Saradha College Road, Salem - 636 007.

0427-2706666 / 87540 33833

info@shanmugahospital.com | www.shanmugahospital.com





P P N AND COMPANY

CHARTERED ACCOUNTANTS

No.2, IV Cross Street, Sterling Road, Nungambakkam, Chennai - 600 034.

(Near to Loyola College) Ph: 044-2828 0033, Cell: 98844 48912.

E-mail: info@ppnaco.com | Web: www.ppnaco.com | www.ppnaco.co.in

UTILIZATION OF IPO FUNDS CERTIFICATE OF M/s SHANMUGA HOSPITAL LIMITED

To,
The Board of Directors,
M/s SHANMUGA HOSPITAL LIMITED
(Formerly known as Shanmuga Hospital Private Limited)
51/24, Saradha College Road,
Salem - 636007,
Tamil Nadu, India.

Respected Sir/Madam,

Sub: Utilisation Certificate for IPO Proceeds dated March 31st, 2025 for expenditure incurred in relation to the initial offer proceeds of public issue for SHANMUGA HOSPITAL LIMITED ("the Company")

We have been requested to certify expenditure incurred by the Company in relation to the Initial Public Offer proceeds. For the purpose of certifying the below table, we have reviewed documents, statement, papers, accounts etc. of the Company on the proceeds of Public Issue, based on our review of the same, we hereby certify that up to March 31st, 2025 the Company has incurred following expenditure are mentioned below:

Sr. No.	Object as disclosed in the Offer Document	Amount disclosed in the Offer Document (Rs. In Lakhs)	Actual Utilised Amount (Rs. In Lakhs)	Unutilised Amount (Rs. In Lakhs)	Remarks
1	Capital Expenditure	1,452.50	337.00	1115.50	The unutilized amount is in the form of Fixed Deposits for future utilization. The Unutilised portion is proposed to be utilised within the month of May 2025
2	Issue related expenses	225.94	225.94	-	Nil
3	General Corporate Purposes	383.28	383.28	-	Nil

We inform you that there has been no deviation(s) or variation(s) in the use of public issue proceeds, raised from the Initial Public offer (IPO) by the company for the Year ended March 31st, 2025.

List of IPO funds received:

Date	Particulars	Amount (Rs. In Lakhs)
21-02-2025	IPO Funds	2,061.72
Total		2,061.72

Yours faithfully,
For P P N AND COMPANY
Chartered Accountants
Firm Reg No: 013623S
Peer Review Certificate No. 013578

R. Rajaram

R. Rajaram
Partner
Membership Number: 238452
UDIN: 25238452BMHSTZ9217

Place: 26/05/2025
Date: Chennai

